FDMT Stock Recent News

4D Molecular Therapeutics, Inc. has faced setbacks, with the FDA placing a clinical hold on its Fabry Disease program due to serious kidney conditions in patients. The company has five product candidates in clinical trials, targeting ophthalmology, cardiology, and pulmonology. The cystic fibrosis program with 4D-710 showed success, with improvements in lung function and quality of life, providing a potential breathing space for patients ineligible for other treatments.

EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today that management will present company overviews and participate in fireside chats at upcoming investor conferences in September and October. Members of the management team will also be available for one-on-one meetings in connection with these meetings.

4D Molecular Therapeutics demonstrates a robust economic position and promising line-up of gene therapies, with a commitment to innovation and strategic financial management. The company's financials show a steady growth trajectory, with successful fundraising efforts, strategic cost management, and investment in research and development. 4DMT's gene therapy products offer potential solutions for a variety of severe ailments, but also face potential challenges and competition in the rapidly evolving field of gene therapy.

Shares of "directed evolution" genetic medicine concern 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. The company's approach to AAV delivery could change the industry, but results have been spotty, featuring a Fabry disease program on clinical hold and two others abandoned by Roche. A full investment analysis follows in the paragraphs below.

EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following upcoming investor conferences:

Viking Global Investors LP, the firm managed by Andreas Halvorsen (Trades, Portfolio), disclosed in a regulatory filing that it boosted its holding in 4D Molecular Therapeutics ( FDMT , Financial) in May according to GuruFocus Real-Time Picks, a Premium feature based on Schedule 13D, 13G and Form 4 filings.

4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

With its strong focus on product design and development excellence, as evidenced by its sustained success in IND clearance, 4D Molecular Therapeutics is a promising biotech company with significant growth. 4D Molecular Therapeutics' recently released data from its PRISM clinical trial for wet age-related macular degeneration (wet AMD) further validates its R100 intravitreal vector's potential for treating large-market eye diseases.

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?